IL195269A0 - Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic - Google Patents

Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic

Info

Publication number: IL195269A0
Authority: IL; Israel
Prior art keywords: applications; well; active ingredient; sustained release; pharmaceutical formulations
Prior art date: 2006-06-09

Application number

IL195269A

Other versions

IL195269A (en

Original Assignee

Flamel Tech Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-06-09

Filing date

2008-11-13

Publication date

2009-08-03

2008-11-13 Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa

2009-08-03 Publication of IL195269A0 publication Critical patent/IL195269A0/en

2014-06-30 Publication of IL195269A publication Critical patent/IL195269A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Addiction (AREA)
Psychiatry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL195269A 2006-06-09 2008-11-13 Pharmaceutical formulations for the prolonged release of active principle(s) and their applications, especially therapeutic applications IL195269A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0605152A FR2902007B1 (en)	2006-06-09	2006-06-09	PHARMACEUTICAL FORMULATIONS FOR PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
PCT/EP2007/055720 WO2007141344A2 (en)	2006-06-09	2007-06-11	Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic

Publications (2)

Publication Number	Publication Date
IL195269A0 true IL195269A0 (en)	2009-08-03
IL195269A IL195269A (en)	2014-06-30

Family

ID=37603185

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL195269A IL195269A (en)	2006-06-09	2008-11-13	Pharmaceutical formulations for the prolonged release of active principle(s) and their applications, especially therapeutic applications

Country Status (14)

Country	Link
EP (1)	EP2043600B1 (en)
JP (1)	JP5351015B2 (en)
KR (2)	KR101463952B1 (en)
CN (1)	CN101466353B (en)
AU (1)	AU2007255367B2 (en)
BR (1)	BRPI0712142A8 (en)
CA (1)	CA2653537C (en)
ES (1)	ES2642095T3 (en)
FR (1)	FR2902007B1 (en)
IL (1)	IL195269A (en)
MX (1)	MX2008015665A (en)
PT (1)	PT2043600T (en)
WO (1)	WO2007141344A2 (en)
ZA (1)	ZA200809864B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2915684B1 (en) *	2007-05-03	2011-01-14	Flamel Tech Sa	PARTICLES BASED ON POLYELECTROLYTES AND MODIFIED RELEASE ACTIVE INGREDIENTS AND PHARMACEUTICAL FORMULATIONS CONTAINING THESE PARTICLES
FR2954325B1 (en)	2009-12-23	2012-02-03	Flamel Tech Sa	AMPHIPHILIC POLYMER FUNCTIONALIZED BY METHIONINE
JP4829351B2 (en)	2010-02-05	2011-12-07	ナノキャリア株式会社	Easily disintegrating polymer micelle composition
KR101198137B1 (en)	2010-09-03	2012-11-12	에스케이하이닉스 주식회사	Write Driver, Semiconductor Memory Apparatus and Program Method Using the Same
FR2968994B1 (en) *	2010-12-17	2012-12-28	Flamel Tech Sa	PROCESS FOR THE PREPARATION OF NANOPARTICLES
FR2968993B1 (en) *	2010-12-17	2012-12-28	Flamel Tech Sa	NANOPARTICLES COMPRISING AT LEAST ONE ACTIVE AND AT LEAST TWO POLYELECTROLYTES
KR101239492B1 (en) *	2011-03-25	2013-03-05	서울대학교산학협력단	Polysorbitol-based osmotically active transporter and gene therapy using the same as a gene carrier
BR112014002986A2 (en)	2011-08-10	2017-06-13	Adocia	composition in the form of a solution for injection, and single dose formulation
CN102432695B (en) *	2011-10-28	2014-02-26	黑龙江大学	Preparation method of N-2-hydroxypropyltrimethylammonium chloride chitosan loaded Newcastle disease live attenuated vaccine nanoparticles
FR2985429B1 (en) *	2012-01-09	2016-07-29	Adocia	PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS
FR2985428B1 (en) *	2012-01-09	2016-05-27	Adocia	PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACIDE
WO2013104861A1 (en) *	2012-01-09	2013-07-18	Adocia	Injectable solution having a ph of 7 and including at least basal insulin, the pi of which is between 5.8 and 8.5, and a substituted co-poly(amino acid)
CN104364292B (en) *	2012-04-13	2018-02-02	韦克森林大学	Low band gaps combination polymeric compositions and its application
US20150314003A2 (en)	2012-08-09	2015-11-05	Adocia	Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
EP3064213A4 (en) *	2013-10-28	2017-04-26	Terumo Kabushiki Kaisha	Protein aqueous suspension
CA2965759C (en)	2014-10-31	2023-12-12	Glaxosmithkline Intellectual Property Development Limited	Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
MX2018015070A (en) *	2016-06-07	2019-05-09	Adocia	Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid.
KR102218427B1 (en) *	2017-09-20	2021-02-22	차의과학대학교 산학협력단	Coacervate composition comprising protein drug and wound healing agent comprising the same
WO2022126100A1 (en) *	2020-12-09	2022-06-16	Lynthera Corporation	Boundary surface charged contact lens for delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5500161A (en) *	1993-09-21	1996-03-19	Massachusetts Institute Of Technology And Virus Research Institute	Method for making hydrophobic polymeric microparticles
FR2732218B1 (en) *	1995-03-28	1997-08-01	Flamel Tech Sa	PARTICLES BASED ON POLYAMINOACID (S) AND LIKELY TO BE USED AS VECTORS OF ACTIVE INGREDIENT (S) AND PROCESSES FOR THEIR PREPARATION
WO1998007410A1 (en) *	1996-08-19	1998-02-26	Vivorx Pharmaceuticals, Inc.	Methods for the production of protein particles useful for delivery of pharmacological agents
FR2786098B1 (en) *	1998-11-20	2003-05-30	Flamel Tech Sa	POLYAMINOACID-BASED PARTICLES (S) THAT MAY BE USED AS ACTIVE INGREDIENTS (VECTORS), COLLOIDAL SUSPENSION COMPRISING SAME AND METHODS OF MAKING SAME
FR2801226B1 (en) *	1999-11-23	2002-01-25	Flamel Tech Sa	COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION
FR2860516B1 (en) *	2003-10-03	2006-01-13	Flamel Tech Sa	TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2862536B1 (en) *	2003-11-21	2007-11-23	Flamel Tech Sa	PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS

2006
- 2006-06-09 FR FR0605152A patent/FR2902007B1/en active Active
2007
- 2007-06-11 JP JP2009513711A patent/JP5351015B2/en active Active
- 2007-06-11 EP EP07730058.0A patent/EP2043600B1/en active Active
- 2007-06-11 ES ES07730058.0T patent/ES2642095T3/en active Active
- 2007-06-11 CA CA2653537A patent/CA2653537C/en active Active
- 2007-06-11 BR BRPI0712142A patent/BRPI0712142A8/en not_active Application Discontinuation
- 2007-06-11 WO PCT/EP2007/055720 patent/WO2007141344A2/en not_active Ceased
- 2007-06-11 AU AU2007255367A patent/AU2007255367B2/en active Active
- 2007-06-11 PT PT77300580T patent/PT2043600T/en unknown
- 2007-06-11 MX MX2008015665A patent/MX2008015665A/en active IP Right Grant
- 2007-06-11 KR KR1020097000533A patent/KR101463952B1/en not_active Expired - Fee Related
- 2007-06-11 KR KR1020147023768A patent/KR20140109512A/en not_active Ceased
- 2007-06-11 CN CN200780021416.XA patent/CN101466353B/en active Active
- 2007-06-11 ZA ZA200809864A patent/ZA200809864B/en unknown
2008
- 2008-11-13 IL IL195269A patent/IL195269A/en active IP Right Grant

Also Published As

Publication number	Publication date
MX2008015665A (en)	2009-01-09
AU2007255367A1 (en)	2007-12-13
EP2043600A2 (en)	2009-04-08
CN101466353A (en)	2009-06-24
IL195269A (en)	2014-06-30
CA2653537A1 (en)	2007-12-13
WO2007141344A3 (en)	2008-04-10
PT2043600T (en)	2017-10-13
JP5351015B2 (en)	2013-11-27
BRPI0712142A8 (en)	2016-03-29
KR20090040289A (en)	2009-04-23
JP2009539810A (en)	2009-11-19
CA2653537C (en)	2014-07-29
KR20140109512A (en)	2014-09-15
CN101466353B (en)	2014-09-03
KR101463952B1 (en)	2014-11-26
WO2007141344A2 (en)	2007-12-13
FR2902007B1 (en)	2012-01-13
AU2007255367B2 (en)	2012-08-02
EP2043600B1 (en)	2017-07-26
WO2007141344B1 (en)	2008-05-22
BRPI0712142A2 (en)	2012-01-10
FR2902007A1 (en)	2007-12-14
ES2642095T3 (en)	2017-11-15
ZA200809864B (en)	2010-03-31

Publication	Publication Date	Title
IL195269A0 (en)	2009-08-03	Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
TWI366460B (en)	2012-06-21	Cannabinoid active pharmaceutical ingredient for improved dosage forms
ZA200705530B (en)	2008-10-29	Sustained release pharmaceutical formulations
ZA200900345B (en)	2010-05-26	Preparation of pharmaceutical formulations
IL199397A (en)	2014-07-31	Heterocyclic compounds, pharmaceutical compositions comprising them and medical uses thereof
IL212435A (en)	2015-06-30	Isoindoline compounds, pharmaceutical compositions comprising the same and use thereof for the preparation of medicaments
IL185390A (en)	2017-06-29	Solid pharmaceutical dosage formulation
IL199835A (en)	2017-09-28	Acid activated antimicrobial peptides, pharmaceutical compositions comprising the same and use thereof for the preparation of medicaments
WO2009117130A3 (en)	2010-01-28	Extended release forumulation containing a wax
EP2112925A4 (en)	2013-01-09	Solid pharmaceutical dosage formulations
EP2045253A4 (en)	2013-01-23	alpha-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
WO2010021607A3 (en)	2010-06-03	Pharmaceutical formulation
IL190698A0 (en)	2008-11-03	Nanoparticulate active ingredient formulations
IL201465A0 (en)	2010-05-31	Self-precipitating pharmaceutical formulations for the modified release of active principle
WO2011019326A3 (en)	2011-04-28	Solubility and stability enchancing pharmaceutical formulation
IL201418A0 (en)	2010-06-16	Therapeutic agent for glaucoma containing adenosine derivative as active ingredient
IL191758A0 (en)	2008-12-29	Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
WO2007090661A3 (en)	2007-09-20	Active substance combination comprising azolylcarbinol compounds
ZA200709788B (en)	2008-08-27	Cannabinold active pharmaceutical ingredient for Improved dosage forms
EP1895991A4 (en)	2012-11-07	Modified release formulations of anti-irritability drugs
IL180031A0 (en)	2007-05-15	Stable pharmaceutical formulations of benzimidazole compounds
EP2196463A4 (en)	2011-08-17	Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof
WO2008004100A9 (en)	2012-04-19	Therapeutic compounds
IL195062A0 (en)	2009-08-03	Process for the preparation of solid sterile active pharmaceutical ingredient
EP1753405A4 (en)	2008-09-17	Controlled release pharmaceutical formulation

Legal Events

Date	Code	Title
2014-10-30	FF	Patent granted
2014-11-30	KB	Patent renewed
2017-06-29	KB	Patent renewed